Kezar Life Sciences Inc (KZR) - Total Assets
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) holds total assets worth $68.00 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Kezar Life Sciences Inc (KZR) net asset quality to measure how much of total assets are equity-financed.
Kezar Life Sciences Inc - Total Assets Trend (2016–2025)
This chart illustrates how Kezar Life Sciences Inc's total assets have evolved over time, based on quarterly financial data. Check Kezar Life Sciences Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Kezar Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kezar Life Sciences Inc's total assets of $68.00 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.8% |
| Accounts Receivable | $1.93 Million | 2.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Kezar Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KZR market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kezar Life Sciences Inc's current assets represent 98.8% of total assets in 2025, an increase from 91.8% in 2016.
- Cash Position: Cash and equivalents constituted 93.8% of total assets in 2025, up from 85.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.5% of total assets.
Kezar Life Sciences Inc Competitors by Total Assets
Key competitors of Kezar Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Kezar Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.46 | 7.09 | 22.43 |
| Quick Ratio | 24.46 | 7.09 | 22.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $64.80 Million | $103.36 Million | $127.40 Million |
Kezar Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Kezar Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -47.0% |
| Total Assets | $76.65 Million |
| Market Capitalization | $1.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kezar Life Sciences Inc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kezar Life Sciences Inc's assets decreased by 47.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kezar Life Sciences Inc (2016–2025)
The table below shows the annual total assets of Kezar Life Sciences Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $76.65 Million | -47.02% |
| 2024-12-31 | $144.68 Million | -34.60% |
| 2023-12-31 | $221.24 Million | -26.15% |
| 2022-12-31 | $299.57 Million | +37.46% |
| 2021-12-31 | $217.93 Million | +43.53% |
| 2020-12-31 | $151.84 Million | +69.63% |
| 2019-12-31 | $89.51 Million | -21.95% |
| 2018-12-31 | $114.68 Million | +111.50% |
| 2017-12-31 | $54.22 Million | +374.63% |
| 2016-12-31 | $11.42 Million | -- |
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more